Contact Us
800.227.0627

CEF Control Peptide Pool HLA-A24 (0.5 mgs)

CEF Control Peptide Pool HLA-A24 (0.5 mgs)
Catalog :
13691-04
Price/Unit:
$1,268  (For other quantities please Contact Us or call 972-420-8505 (USA) 800-227-0627 (INTL.) or Fax 972.420.0442)
Purity:
>95%
Format:
Each vial contains 4 mgs lyophilized peptide - 8 individual peptides with 0.5 mgs each.
Description:

This CEF control peptide pool contains 0.5 mgs of the 8 CEF Control HLA-A24 peptides for the total of 4 mg in one vial. This 8 HLA-A24 peptides restricted T-cell epitopes from human Cytomegalovirus and Epstein-Barr virus. The CE-Pool stimulates the release of IFN-gamma from CD8+ T-cells in individuals with the HLA-A24 type and is the most frequent type in Asian populations, existent is approximately 70% of the Japanese population. It is also found in about 35% of the Indian population. CE Peptide Pool is useful as a peptidespecific positive control in ELISPOT, CTL and Intracellular Cytokine Assays using human PBMC.

HLA Allele Virus Peptide Sequence Cat #
All of  the below Pooled Peptides All of the below 13690-05
EBNA3 EBV RYSIFFDY  
LMP-2 EBV TYGPVFMC  
EBNA-3 EBV TYSAGIVQI  
BRLF-1  EBV TYPVLEEMF  
BMLF-1 EBV DYNFVKQLF  
pp65 CMV QYDPVAALF  
  CMV VYALPLKML  
Rta 28-37 EBV DYCNVLNKEF  

Storage:
Store the peptide at -20°C. Keep container tightly
Product Usage:
This product is for research use only. Not for use in diagnostic or therapeutic procedures.
Reference/Citations:
  1. Immunol Lett. 2002 Aug 1;83(1):21-30. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Akiyama Y, Maruyama K, Mochizuki T, Sasaki K, Takaue Y, Yamaguchi K.
  2. Viral Immunol. 2001;14(4):369-77. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Masuoka M, Yoshimuta T, Hamada M, Okamoto M, Fumimori T, Honda J, Oizumi K, Itoh K.
  3. J Gen Virol. 1994 Sep;75 ( Pt 9):2489-93. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. Burrows SR, Gardner J, Khanna R, Steward T, Moss DJ, Rodda S, Suhrbier A.
  4. J Immunol. 1997 Apr 1;158(7):3325-34. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB.
  5. J Virol. 1998 Nov;72(11):8644-9. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. Pepperl S, Benninger-Doring G, Modrow S, Wolf H, Jilg W.
  6. Blood. 2003 Feb 15;101(4):1460-8. Epub 2002 Sep 26. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells. Kuzushima K, Hayashi N, Kudoh A, Akatsuka Y, Tsujimura K, Morishima Y, Tsurumi T.